URAC Opioid Stewardship Designation: IHS Consulting Approach

Last updated: April 2026

This page illustrates how IHS structures a URAC Opioid Stewardship Designation engagement — the problems organizations typically bring to us, how we approach the work, and what the path to designation looks like in practice. The engagement profile below is drawn from the types of organizations IHS routinely works with. Client identities are confidential.

IHS is led by Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC — the organization that wrote these standards.

Engagement Profile: Regional Specialty Pharmacy Pursuing Concurrent Designation

Organization Background

A regional specialty pharmacy operating across multiple states, dispensing controlled substances including opioids for oncology, chronic pain, and post-surgical patient populations. The pharmacy was pursuing URAC Specialty Pharmacy Accreditation for the first time in response to a major payer network requirement and wanted to pursue the Opioid Stewardship Designation concurrently — having identified it as a potential differentiator in a competitive regional market where two competing specialty pharmacies already held URAC accreditation.

The pharmacy's leadership understood opioid stewardship conceptually — they had adopted elements of the American Society of Health-System Pharmacists (ASHP) opioid stewardship framework and participated in their state's PDMP. What they had not done was translate those activities into URAC-specific documented evidence. The designation review would evaluate URAC's interpretive information — not ASHP's framework.

What the Organization Brought to IHS

  • Informal opioid dispensing protocols — verbal in some areas, documented in a legacy policy manual that had not been reviewed in three years
  • PDMP registration and query logs, but no documentation connecting those queries to a patient safety escalation protocol
  • A pharmacist-led opioid counseling practice — inconsistently documented, with no standardized records of patient risk screening
  • Staff who were knowledgeable about opioid stewardship in practice but had no training records that URAC reviewers could evaluate
  • No governance structure assigning executive accountability for opioid stewardship outcomes

This is a typical starting position. The pharmacy was operationally sophisticated — the gap was documentation and URAC-specific alignment, not competency.

Phase 1: Eligibility Confirmation and Gap Assessment

Confirming Eligibility

IHS first confirmed that the pharmacy met the two eligibility requirements for the Opioid Stewardship Designation: (1) the organization was actively pursuing URAC Specialty Pharmacy Accreditation — a qualifying associated program — and (2) the organization's operations directly impacted patient access to opioid medications. Both criteria were clearly met.

Gap Assessment Against the Four Standards

IHS conducted a gap assessment mapping the pharmacy's existing operations against each of the four Opioid Stewardship Designation standards and their associated URAC interpretive information. The assessment identified:

Standard 1: Patient Safety in Opioid Medication Management

Gap identified: The pharmacy had dispensing safety checks in place but no documented protocol specifying how high-risk patients (those on long-term high-dose opioids, concurrent benzodiazepine users, patients with prior substance use disorder history) were identified and managed differently. PDMP queries were occurring but were not systematically documented in patient records with a defined workflow.

IHS approach: Develop a risk stratification protocol aligned with URAC's patient safety standard, integrate PDMP query documentation into the patient record workflow, and create a standardized high-risk patient management protocol with defined pharmacist touchpoints.

Standard 2: Appropriate Opioid Use

Gap identified: The pharmacy's clinical pharmacists conducted prospective drug utilization review (DUR) on opioid prescriptions, but the review criteria were informal and undocumented. There was no written protocol defining what triggered pharmacist intervention, how interventions were documented, or how prescriber communications were recorded.

IHS approach: Develop a written DUR protocol for opioid prescriptions with defined intervention criteria, documentation requirements, and prescriber communication templates. Align with URAC's interpretive information for the appropriate use standard.

Standard 3: Innovation in Opioid Management and Monitoring

Gap identified: The pharmacy was using basic dispensing system reports for opioid utilization review but had no structured program for monitoring prescribing patterns, identifying outliers, or tracking patient outcomes. The data existed; the analysis framework and documentation did not.

IHS approach: Design a monthly opioid utilization monitoring framework using existing dispensing system data, establish documentation requirements for analysis outputs, and create an escalation pathway for outlier findings. This standard rewards organizations that can show systematic, documented monitoring — not just access to data.

Standard 4: Substance Use Disorder Risk Reduction

Gap identified: Pharmacists were conducting patient counseling on opioid risks and naloxone availability, but counseling records were inconsistent and training records for staff delivering the counseling did not exist. There was no documented protocol for identifying patients at elevated risk for opioid use disorder or for connecting those patients to treatment resources.

IHS approach: Develop a standardized patient counseling protocol with documentation requirements, create a SUD risk screening tool aligned with validated instruments, establish a referral pathway to SUD treatment resources, and build staff training records demonstrating competency in the protocol.

Phase 2: Policy and Documentation Development

Integration with Primary Accreditation Documentation

Because the pharmacy was simultaneously pursuing URAC Specialty Pharmacy Accreditation, IHS structured the Opioid Stewardship Designation documentation to build on — not duplicate or contradict — the primary accreditation evidence framework. Patient safety protocols developed for the designation were cross-referenced with the pharmacy's quality management program required for Specialty Pharmacy Accreditation. Staff training records built for the designation were integrated into the broader staff competency documentation required by primary accreditation standards.

This integration is the primary efficiency gain from concurrent pursuit. Organizations that treat the designation as a separate workstream build twice as much documentation with higher risk of internal inconsistency. IHS prevents that from the outset by designing a unified documentation architecture.

What IHS Provided

  • High-risk patient identification protocol — written protocol defining risk stratification criteria, PDMP query documentation requirements, and high-risk patient management workflow aligned with URAC Standard 1 interpretive information
  • Opioid DUR protocol — documented criteria for pharmacist intervention on opioid prescriptions, intervention documentation templates, and prescriber communication records aligned with Standard 2
  • Monthly opioid utilization monitoring framework — data elements, analysis methodology, documentation format, and escalation pathway for outlier findings aligned with Standard 3
  • SUD risk screening and counseling protocol — risk screening tool, standardized counseling documentation, naloxone co-dispensing records, and SUD referral pathway aligned with Standard 4
  • Staff training curriculum and records framework — training content for all four standard areas, competency assessment documentation, and annual training refresh requirements
  • Governance documentation — leadership accountability assignment for opioid stewardship, committee oversight records, and annual program review requirements

Template Adaptation

IHS provides templates — your team adapts them to reflect your organization's actual operations, patient population, and clinical workflows. IHS reviews adapted versions for URAC alignment before they are finalized. Templates that do not reflect operational reality fail URAC's review. The adaptation step is not optional.

Phase 3: Operational Implementation and Evidence Generation

The Documentation Gap That Catches Organizations

Policies must be operationally live — generating audit-ready evidence — before the URAC review date. An organization that writes a high-risk patient protocol in month 8 of a 12-month engagement has policies that are three months old. URAC reviewers evaluate whether the documented program is real: they look for operational evidence — completed risk screenings, documented DUR interventions, utilization monitoring reports, training attendance records — not just policy binders.

For this engagement, IHS established an implementation timeline that ensured all four standard areas were generating documented evidence at least four months before the URAC review date. This is the operational compliance window, not the documentation drafting window.

Mock Review

IHS conducted an internal mock review across all four Opioid Stewardship Designation standards before the formal URAC application was submitted. The mock review identified two gaps in the SUD risk screening documentation — counseling records were inconsistent in format, and several records lacked the specific elements URAC's interpretive information requires. These were corrected before submission.

The mock review is where preventable failures are caught. Organizations that submit without a mock review discover their gaps during the URAC review — after the application is already in progress.

Phase 4: Application and Review

Application Submission

The Opioid Stewardship Designation application was submitted concurrently with the Specialty Pharmacy Accreditation application. URAC reviewed both the primary accreditation and the designation documentation. Having a single point of contact at IHS for both submissions streamlined the process and ensured consistent documentation across both applications.

URAC's Review

URAC's desktop review of the designation evaluated the four standards against the submitted policies, protocols, and operational evidence. URAC issued one Request for Information (RFI) on the utilization monitoring framework — requesting additional detail on the escalation pathway for outlier prescribers. IHS drafted the RFI response and assembled the supporting documentation within URAC's response window. No additional RFIs were issued.

Outcome

The pharmacy received both URAC Specialty Pharmacy Accreditation and the Opioid Stewardship Designation. The concurrent pursuit added meaningful documentation effort but significantly less than pursuing the designation sequentially after accreditation would have required — because foundational patient safety and quality management infrastructure was being built for both programs simultaneously.

The pharmacy subsequently used the designation in payer contract negotiations with two regional health plans that had indicated opioid stewardship documentation as a preferred-vendor criterion. It also used the designation in its network participation application to a specialty pharmacy benefit manager that explicitly listed URAC Opioid Stewardship Designation as a differentiating factor in network selection.

What This Engagement Illustrates

Concurrent Pursuit Is the Right Default

When a pharmacy is building clinical protocols, patient safety documentation, and staff training infrastructure for Specialty Pharmacy Accreditation, the marginal effort for the Opioid Stewardship Designation is substantially lower than pursuing it separately. The question is whether to integrate from the start — not whether to pursue both.

Operational Documentation Is the Gap, Not Competency

This pharmacy was clinically sophisticated. Its pharmacists understood opioid stewardship better than many organizations that hold the designation. The gap was systematic documentation that translated operational competency into URAC-reviewable evidence. That is the gap IHS addresses — not pharmacist competency, but the documentation and governance infrastructure that URAC evaluates.

URAC-Specific Interpretive Knowledge Matters

The pharmacy had applied ASHP opioid stewardship framework elements to its operations. That framework is clinically sound — but it does not map directly to URAC's interpretive information. Generic opioid stewardship frameworks produce policies that satisfy the spirit but not the letter of URAC's evaluation criteria. Thomas G. Goddard, JD, PhD — former Chief Operating Officer and General Counsel of URAC — brings authoritative knowledge of how URAC constructs, interprets, and applies its standards. That is what IHS provides.

The Mock Review Catches What Surveyors Would Catch

The SUD risk screening documentation gaps identified in the mock review were exactly the type of deficiency URAC's reviewers look for. Identifying and correcting those gaps before submission — rather than during the URAC review — kept the engagement on schedule and prevented an RFI in the most documentation-intensive standard area.

IHS Consulting Approach for the Opioid Stewardship Designation

Every IHS engagement for the URAC Opioid Stewardship Designation follows the same architecture:

  1. Eligibility confirmation — verify associated program qualification and operational scope
  2. Gap assessment — map existing operations against all four standards and URAC interpretive information; identify what is missing versus what needs to be formalized
  3. Integrated documentation build — provide templates, review adaptations for URAC alignment, and integrate with primary accreditation documentation to prevent redundancy and inconsistency
  4. Implementation monitoring — track operational evidence generation across all four standard areas; establish timeline to ensure sufficient evidence before the review date
  5. Mock review — internal review against all four standards before submission; correct deficiencies before URAC does
  6. Application and RFI support — coordinate submission; draft and support RFI responses through committee decision

IHS does not produce policy binders. We build operational compliance and the documentation that proves it — evaluated against the interpretive information that URAC's reviewers actually use.

Related Resources

Ready to Pursue the URAC Opioid Stewardship Designation?

Schedule a no-obligation consultation with IHS. We will assess your eligibility, identify the fastest integrated path to the designation alongside your primary URAC program, and give you a clear roadmap with realistic timelines.

Schedule a Free Discovery Session